Want to see RMTG full AI Analyst Report?
Top Page
Regenerative Medical Technology Group
(OTC:RMTG)
Select Model
Select Model
Rating:49Neutral
Price Target:
$0.09
▲(345.00% Upside)
Action:Reiterated
Date:07/18/26
The score is primarily held down by weak financial performance—very large ongoing losses, negative equity, and negative free cash flow—despite solid revenue growth and gross margins. Technical indicators provide a meaningful offset with positive momentum and price trading above key moving averages. Valuation remains a secondary drag due to losses (negative P/E) and no dividend support.
Positive Factors
Revenue Growth
Sustained double-digit revenue growth provides a durable foundation for the business model: expanding top-line supports future operating leverage, validates market demand, and creates optionality to invest in sales and R&D over the next several quarters without relying solely on one-time events.
Negative Factors
Large Net Losses
Very large recurring net losses erode retained capital and limit reinvestment capacity. Persistent negative profitability undermines ability to self-fund growth, forces reliance on external financing, and increases dilution risk unless the company converts revenue and margin progress into sustained operating profits.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained double-digit revenue growth provides a durable foundation for the business model: expanding top-line supports future operating leverage, validates market demand, and creates optionality to invest in sales and R&D over the next several quarters without relying solely on one-time events.
Read all positive factors
Regenerative Medical Technology Group (RMTG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.17M
Dividend YieldN/A
Average Volume (3M)8.37K
Price to Earnings (P/E)―
Beta (1Y)-1.35
Revenue Growth36.96%
EPS Growth-79.17%
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustrySpecialty Business Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding13,138,968
10 Day Avg. Volume641
30 Day Avg. Volume8,365
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.02
Price to Sales (P/S)0.12
P/FCF Ratio-0.47
Enterprise Value/Market Cap17.15
Enterprise Value/Revenue3.15
Enterprise Value/Gross Profit5.52
Enterprise Value/Ebitda17.55
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Regenerative Medical Technology Group Business Overview & Revenue Model
Company Description
Regenerative Medical Technology Group Inc. operates in the regenerative medicine industry in the United States and internationally. It provides products, solutions, equipment, services, and training to doctors and their staff in the application of...
Regenerative Medical Technology Group Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
18
Very Negative
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.38M | 5.10M | 4.11M | 2.41M | 1.53M | 437.89K |
| Gross Profit | 3.63M | 2.81M | 2.82M | 1.68M | 876.97K | 150.14K |
| EBITDA | 1.14M | -83.56K | 301.74K | -3.01M | -1.02M | -10.11M |
| Net Income | -7.93M | -7.81M | -5.56M | -9.81M | -5.49M | -12.88M |
Balance Sheet | ||||||
| Total Assets | 5.01M | 4.49M | 3.82M | 2.88M | 8.08M | 9.31M |
| Cash, Cash Equivalents and Short-Term Investments | 1.06M | 956.72K | 1.17M | 530.54K | 1.65M | 2.98M |
| Total Debt | 20.58M | 19.57M | 20.05M | 17.65M | 15.14M | 13.37M |
| Total Liabilities | 40.63M | 39.23M | 31.18M | 24.67M | 20.06M | 16.06M |
| Stockholders Equity | -35.62M | -34.75M | -27.36M | -21.80M | -11.98M | -6.76M |
Cash Flow | ||||||
| Free Cash Flow | -1.58M | -1.31M | 635.28K | -804.80K | -1.31M | -9.88M |
| Operating Cash Flow | -661.50K | -706.52K | 850.70K | -419.20K | -1.11M | -9.88M |
| Investing Cash Flow | -917.98K | -602.58K | -215.42K | -385.60K | -198.43K | 666.47K |
| Financing Cash Flow | 1.42M | 1.10M | 0.00 | -309.85K | -20.78K | 12.15M |
Regenerative Medical Technology Group Risk Analysis
Regenerative Medical Technology Group disclosed 37 risk factors in its most recent earnings report. Regenerative Medical Technology Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Regenerative Medical Technology Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.17M | -0.13 | 24.65% | ― | 36.96% | -79.17% | |
47 Neutral | $4.81M | -0.19 | ― | ― | ― | ― | |
44 Neutral | $1.50M | -0.09 | -145.52% | ― | ― | 98.81% | |
43 Neutral | $1.86M | -0.04 | -471.55% | ― | 9.50% | 90.44% |
* Healthcare Sector Average
RMTG
Regenerative Medical Technology Group
0.09
0.03
48.33%
BBLG
Bone Biologics
1.17
-1.81
-60.74%
IVF
INVO Fertility
1.04
-100.96
-98.98%
BJDX
Bluejay Diagnostics
1.45
-4.79
-76.76%
NIVF
NewGenIvf Group
1.32
-483.78
-99.73%
WOK
WORK Medical Technology Group LTD
1.99
-819,397.91
-100.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.